Aducanumab, Lecanemab for Early AD: The Clinical Trials That Led to FDA Approval
These are the clinical trials that led to the FDA’s approval of aducanumab and lecanemab for early AD, plus, the concerns that loom.
These are the clinical trials that led to the FDA’s approval of aducanumab and lecanemab for early AD, plus, the concerns that loom.
Researchers sought to analyze brain concentrations of vitamin D and assess whether there were any associations with cognitive and neuropathology outcomes.
AXS-05 is an investigational agent consisting of a proprietary formulation of dextromethorphan and bupropion.
Gantenerumab is an investigational immunoglobulin G1 antibody designed to increase the clearance of soluble amyloid beta from the brain.
Researchers sought to evaluate the efficacy of noradrenergic drugs in the improvement of neuropsychiatric and cognitive symptoms in individuals with AD.
Ines Moreno-Gonzalez, PhD, an adjunct associate professor of neurology, explains healthy aging can help reduce lifestyle risk factors for Alzheimer disease.
Crenezumab is an investigational monoclonal antibody designed to neutralize neurotoxic oligomers, a form of beta-amyloid.
Researchers sought to evaluate whether there is any evidence from real-world data on treatment with tofacitinib, tocilizumab, or tumor necrosis factor and the risk for ADRD.
Researchers established the Florida Consortium for African American Alzheimer’s Disease Studies to identify genetic risk factors and novel plasma biomarkers for AD.
In a cross-sectional study, researchers compared COVID-19 infection and mortality rates from 2019 and 2020 among Medicare enrollees with Alzheimer disease and related dementias.